Related Experiment Video
Updated: Apr 19, 2026
09:22
Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
Published on: February 28, 2021
6.1K
Meta-analysis demonstrates no association between XRCC1 Arg399Gln polymorphism and bladder cancer risk
L M Dong1, X Y Zhang1, H Teng2
1Department of Urological Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Genetics and Molecular Research : GMR
|December 16, 2014
Summary
This meta-analysis found no link between the XRCC1 Arg399Gln polymorphism and bladder cancer risk. The X-ray repair cross-complementing group 1 (XRCC1) gene variant does not appear to increase susceptibility to this cancer.
Area of Science:
- Genetics and Epidemiology
- Cancer Research
- Molecular Biology
Background:
- The X-ray repair cross-complementing group 1 (XRCC1) gene plays a crucial role in DNA single-strand break repair.
- Genetic variations, such as the XRCC1 Arg399Gln polymorphism, are investigated for their potential association with cancer susceptibility.
- Bladder cancer is a significant public health concern, and understanding its risk factors is essential.
Purpose of the Study:
- To investigate the association between the XRCC1 Arg399Gln polymorphism and bladder cancer risk.
- To conduct a comprehensive meta-analysis of existing case-control studies.
Main Methods:
- A systematic literature search was performed in the Pubmed and Embase databases.
- Meta-analysis was conducted on 16 case-control studies comprising 892 bladder cancer cases and 1020 healthy controls.
- Subgroup analyses were performed based on ethnicity.
Main Results:
- No significant association was found between the XRCC1 Arg399Gln polymorphism and bladder cancer risk across various genetic models (allele, homozygote, heterozygote comparisons).
- Odds ratios ranged from 0.89 to 1.13, with confidence intervals crossing 1, indicating no statistically significant effect.
- Subgroup analyses by ethnicity (Caucasian, Mongoloid, black) also revealed no significant association.
Conclusions:
- The XRCC1 Arg399Gln polymorphism is not a significant risk factor for bladder cancer.
- This finding suggests that this specific genetic variation in XRCC1 does not influence an individual's susceptibility to developing bladder cancer.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
74
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
01:11Genome-wide Association Studies-GWAS
17.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
17.2K